HomeBioPharma

BioPharma

BioPharma

Solid says early data suggest ‘differentiated’ Duchenne gene therapy

-

BioPharma

Biogen buys rights to Stoke’s rare epilepsy drug

BioPharma

FTC sues major pharmacy benefit managers over insulin prices

BioPharma

AstraZeneca, Daiichi’s Enhertu successor faces more questions after latest stumble

BioPharma

Biogen, UCB get the lupus data they’ve waited two decades for

BioPharma

J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers

0

BioPharma

The top biopharma conferences in 2025

0

BioPharma

Editas trades Vertex fees for upfront cash in DRI deal

0

BioPharma

Sanofi’s rare disease drug finds yet another home

0

BioPharma

AI startup Basecamp allies with the Broad to dream up ‘programmable’ genetic medicines

0

BioPharma

Sanofi may have found a buyer for its consumer health business

0

BioPharma

Novocure wins FDA approval for electric field device in lung cancer

0

BioPharma

Merck antibody reduces RSV-related disease, hospitalizations in trial

0

BioPharma

Kalaris to go public via reverse merger with AlloVir

0

BioPharma

On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned

0

BioPharma

Trump names RFK Jr. as his pick to lead HHS

0

BioPharma

How a Biogen drug set the stage for a new biotech targeting ALS

0

12 3 4 Page 1 of 4

Most Read

Solid says early data suggest ‘differentiated’ Duchenne gene therapy

Biogen buys rights to Stoke’s rare epilepsy drug

FTC sues major pharmacy benefit managers over insulin prices

Top 10 Companies in Biosimilars Production